Travere Therapeutics, Inc. TVTX Accrued royalty in excess of minimum payable to the sellers of Thiola
Accrued royalty in excess of minimum payable to the sellers of Thiola at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept tvtx:AccruedRoyaltyInExcessOfMinimumPayableToSellers.
The official record: Travere Therapeutics, Inc.’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s accrued royalty in excess of minimum payable to the sellers of thiola.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s accrued royalty in excess of minimum payable to the sellers of thiola?
- Travere Therapeutics, Inc. (TVTX) reported accrued royalty in excess of minimum payable to the sellers of thiola of $3.57M in Q4 2025.
- How has Travere Therapeutics, Inc.'s accrued royalty in excess of minimum payable to the sellers of thiola changed year-over-year?
- Travere Therapeutics, Inc.'s accrued royalty in excess of minimum payable to the sellers of thiola decreased by 7.5% year-over-year, from $3.86M to $3.57M.
- What is the long-term trend for Travere Therapeutics, Inc.'s accrued royalty in excess of minimum payable to the sellers of thiola?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s accrued royalty in excess of minimum payable to the sellers of thiola has grown at a -7.3% compound annual growth rate (CAGR), from $19.36M to $14.28M.
- What does accrued royalty in excess of minimum payable to the sellers of thiola mean?
- Represents the liability for royalty payments that exceed the contractually required minimum, typically triggered by successful product sales performance. This reflects the variable cost structure associated with acquired assets and the success of commercialized products.